CYP3A genotypes of donors but not those of the patients increase the risk of acute rejection in renal transplant recipients on calcineurin inhibitors: a pilot study
- 18 October 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 74 (1), 53-60
- https://doi.org/10.1007/s00228-017-2353-9
Abstract
Purpose We aimed to determine whether polymorphisms in CYP3A genes may affect the risk of acute rejection episodes (ARE) in renal transplant recipients treated with calcineurin inhibitors (CNIs). Methods One hundred and thirty seven patients and their respective donors were screened, by RT-PCR techniques, for three polymorphisms previously related with CNI pharmacokinetics and pharmacodynamics (CYP3A4*1B, CYP3A4*22 and CYP3A5*3). Genotypes of donors and recipients were associated by logistic regression models with ARE risk and exposure to CNIs. Clinical and pharmacokinetic parameters were recorded at four time-points after transplant (1 week and 1, 5 and 12 months). Results Nineteen patients (13.86%) experienced ARE. Patients who received a kidney from a donor carrying the CYP3A4*1B or CYP3A5*1 variant experienced ARE more frequently than those whose donor carried wild-type genotypes [OR = 6.29 (1.62–24.39), p = 0.008 and OR = 3.42 (1.06–11.01), p = 0.039, respectively]. The combined analysis of the CYP3A4*1B/3A5*1 alleles also revealed an increased risk in patients whose donors carried both variants [OR = 6.24 (1.60–24.33), p = 0.007]. The CYP3A genotype of the recipient did not affect ARE risk, although it did determine the degree of exposure to CNI throughout the first year after transplant. Patients with one or two variant alleles displayed lower concentration-to-dose ratios (CDRs) than non-carriers, with differences increasing with time after transplant (p values = 0.039, 0.004, 6.0 e−04 and 2.7 e−07 in the four time-points). Conclusions Our preliminary findings suggest that the determination of the CYP3A genotype of the donor, but not that of the recipient, may be useful to predict the incidence of acute rejection in renal transplantation.Keywords
Funding Information
- Instituto de Salud Carlos III (PI15/00804)
- Association for the Study and Prevention of Renal Diseases (ASEPER)
- Consejería de Economía, Comercio e Innovación, Junta de Extremadura (GR15012)
- Junta de Extremadura (Fondo Europeo de Desarrollo Regional, FEDER) (IB16014)
This publication has 41 references indexed in Scilit:
- Tacrolimus Dose Requirements and CYP3A5 Genotype and the Development of Calcineurin Inhibitor-Associated Nephrotoxicity in Renal Allograft RecipientsTherapeutic Drug Monitoring, 2010
- Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part IIClinical Pharmacokinetics, 2010
- Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part IClinical Pharmacokinetics, 2010
- Association of four DNA polymorphisms with acute rejection after kidney transplantationTransplant International, 2008
- CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipientsPharmacogenetics and Genomics, 2008
- Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipientsPharmacogenetics and Genomics, 2006
- Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients1 2Transplantation, 2003
- Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirementTransplantation, 2002
- ForewordAmerican Journal of Kidney Diseases, 2002
- Clinical Pharmacokinetics of TacrolimusClinical Pharmacokinetics, 1995